Jason Topolosky serves as the Chief Business Officer at OsteoCentric Technologies, where he leverages over 25 years of strategic and corporate development leadership within the medical device and technology sectors. His extensive experience encompasses a diverse range of specialties, including neurosurgery, neurovascular, and craniomaxillofacial applications,...
Jason Topolosky serves as the Chief Business Officer at OsteoCentric Technologies, where he leverages over 25 years of strategic and corporate development leadership within the medical device and technology sectors. His extensive experience encompasses a diverse range of specialties, including neurosurgery, neurovascular, and craniomaxillofacial applications, positioning him as a key player in the advancement of innovative medical solutions. At OsteoCentric, Jason is at the forefront of pioneering less invasive bone preparation techniques and enhancing implant-to-bone integration through the MI Method—UnifiMI, a groundbreaking platform technology that promises improved primary stability across various applications, including spine, trauma, sports medicine, reconstruction, extremity, dental, and veterinary implants.
In his role, Jason leads all corporate development activities, driving targeted mergers and acquisitions (M&A) and facilitating international market entry strategies that align with OsteoCentric's vision for growth. His outstanding track record as a strategist and marketer has resulted in record-breaking revenue and profit growth in highly competitive markets. By fostering partnership expansions and developing differentiated products and services, Jason has positioned OsteoCentric as a leader in the medical device industry. His expertise in strategic planning and sales operations enables him to navigate complex business landscapes effectively, ensuring that OsteoCentric remains at the cutting edge of innovation. With a commitment to enhancing patient outcomes through advanced technology, Jason Topolosky is not just shaping the future of OsteoCentric but also redefining standards within the medical device field.
